What does SPRM stand for?

the Company's Senior VP of Clinical and Regulatory Affairs, said, "Based on our meeting with the FDA, uterine fibroid-induced anemia is a new indication for Proellex which is a realistically achievable goal for what we believe is a best-in-class selective progesterone receptor modulator.

Reasons to Purchase: --Quantify the future size and scope of the market, and the potential for new products --Benchmark pipeline drugs against currently marketed products with drug profiles and SWOT analysis --Measure the impact of key patent expiries using the forecasting model CHAPTER 1 EXECUTIVE SUMMARY CHAPTER 2 PATIENT POTENTIAL CHAPTER 3 R&D APPROACH CHAPTER 4 ENDOMETRIOSIS PIPELINE ANALYSIS CHAPTER 5 GNRH ANTAGONIST LATE-STAGE DRUG ANALYSIS & FORECASTS CHAPTER 6 SELECTIVE PROGESTERONE RECEPTOR MODULATOR CLASS LATE-STAGE DRUG ANALYSIS AND FORECASTS CHAPTER 7 HORMONALS/ANTI-HORMONALS LATE-STAGE ANALYSIS AND FORECASTS CHAPTER 8 OTHER DRUGS LATE-STAGE ANALYSIS AND FORECASTS CHAPTER 9 INNOVATIVE EARLY-STAGE PROJECTS 150 APPENDIX A 161 For more information visit http://www.

The lead compound, named Progenta(TM), a Selective Progesterone Receptor Modulator (SPRM), was selected from a series of compounds developed by the National Institute of Health (NIH).